Andreas Barner, Ph.D, M.D.

Dr. Andreas Barner is Vice Chairman and Member of the Board of Managing Directors of Boehringer Ingelheim GmbH, Germany, responsible for the Corporate Board Division Pharma-Research, Development and Medicine. Prior to this he was Corporate Medical Director responsible for global clinical research, drug regulatory affairs, information & biometry, and drug safety. Prior to this he was Head of the Corporate Medical Department. Dr. Barner joined Boehringer Ingelheim in January 1992 from Ciba-Geigy AG (Novartis) in Basle, Switzerland where he was Head of the Development Indication Area for Inflammatory, Bone and Allergy Diseases within the Research and Development Department. He began his professional career at Ciba-Geigy in the Central Function of Research and the Medical Department. He obtained his medical degree and doctoral degree in Medicine from the University of Freiburg and his PhD in Mathematics from the Swiss Federal Institute of Technology. Dr. Barner is the Chairman of the German Association of Research based Pharmaceutical Companies (VFA) and currently serves as Deputy Chair Person of the NGFN Steering Committee (National Genome Research Network), Member of the EFPIA R&D Directors’ Group, Member of the Advisory Board to the University of Mainz, and Member of the Board of Trustees of the German Chemical Industry Fund.




Gerard M. Edelman, M.D.

Dr. Gerard M. Edelman is the Chairman of NGN Capital’s Advisory Board. Nobel Laureate, Chairman, Neurobiology Scripps Research, Immunologist; born in New York City. He practiced medicine at both Massachusetts General Hospital (1957-60), and the hospital of Rockefeller University. He joined the faculty of Rockefeller (1960-81) and became director of their Neurosciences Institute (1981). He shared the 1972 Nobel Prize in physiology for his investigations of the structure of the primary human antibody, immunoglobulin G. He then focused his research on cellular immune responses and intercellular communication in the immune system and the brain. Dr. Edelman is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, the American Society of Biological Chemists and the American Association of Immunologists, as well as a number of other scientific societies.



Gerard M. Moufflet

Gerard M. Moufflet is CEO of KIKA Medical International, an NGN portfolio company, and CEO and Founder of Acceleration International, a private equity firm investing in the healthcare industry. He has been active in the healthcare field worldwide for over 30 years. From 1989 to 2001 Mr. Moufflet was a Managing Director at Advent International, heading the healthcare team of one of the world's leading private equity investment firms with over $6 billion funds under management. From 1972 to 1989 Mr. Moufflet served as Corporate Vice President of Baxter and Vice President of Baxter World Trade. Mr. Moufflet serves on the board of public U.S. companies American Dental Partners, Curative Health Services, Serologicals Inc. and several private companies including Thommen Medical and Medical Simulation. Mr. Moufflet is also the Chairman of the Board of Fellows of the Harvard Dental School of medicine. Mr. Moufflet is a graduate of the EDHEC Business School in France, holds an MBA (1969) from the University of Pittsburgh. He is a Harvard Business School AMP (1987). He has been honored by the President of France as a "Chevalier de l'Ordre du Merite National".


Photo courtesy of Discovery Communications

Dr. Mehmet C. Oz

Mehmet C. Oz, MD is Vice-Chair and Professor of Surgery at Columbia University. He directs the Cardiovascular Institute and Complementary Medicine Program at New York Presbyterian Hospital. His research interests include heart replacement surgery, minimally invasive cardiac surgery, complementary medicine and health care policy. He has authored over 400 original publications, book chapters, and medical books and has received several patents. He performs over 350 heart operations annually. Dr Oz authored the award winning “Healing from the Heart” (Dutton Penguin Putnam 1998) as well as numerous pieces in Newsweek, Oprah Magazine, and the New England Journal of Medicine. He has a bi-monthly column in Esquire magazine. He also wrote “You: The Owner’s Manual,” (Harper Collins, 2005),which became a New York Times Bestseller. In addition to belonging to every major professional society for heart surgeons, Dr Oz was elected as a Global Leader of Tomorrow by the World Economic Forum, won the prestigious American Association for Thoracic Surgery Gross Research Scholarship, and has received an honorary doctorate from Istanbul University, He was voted "The Best and Brightest" by Esquire Magazine and was elected one of the Doctors of the Year by Hippocrates magazine and Healers of the Millennium by Healthy Living magazine. He is annually elected as one of the best physicians in the U.S. by the Castle Connolly Guide as well as other major ranking groups. Dr. Oz received his undergraduate degree from Harvard University (1982) and obtained a joint MD and MBA (1986) from the University of Pennsylvania School of Medicine and Wharton Business School. He was awarded the Captain’s Athletic Award for leadership in college and was Class President followed by President of the Student Body during medical school.


Peter Sjöstrand, M.D.

Dr. Peter Sjöstrand is currently Chairman of Gambro AB and Chairman of Innate Pharmaceuticals AB in Sweden. He had been Executive Vice President, CFO and temporary CEO of The Astra Group, serving as Member of the Executive Committee and Board of Directors in a career of almost 20 years at Astra (1975-1993). He had regional responsibility for the Americas including the joint venture with Merck & Co and its launch of Prilosec®, which at the time was the largest selling pharmaceutical product blockbuster in U.S. history. Prior to this, Dr. Sjöstrand was Consultant at the Maynard Company since 1970. Dr. Sjöstrand obtained his medical doctor degree at the Karolinska Institute in Stockholm and holds a B.S. in Economics from the Stockholm School of Economics. Dr. Sjöstrand currently serves on the board of the U.S. Carlyle Group’s European advisory Board, as Chairman of the Board of Meda AB, Microdrug AG, Oscar Hirsch Memory Foundation, Jacob Wallenberg’s & Madleine Sager’s Foundation, as Treasurer of the Swedish Heart & Lung Foundation, and as Director of Active Biotech AB. He previously has been a Director of Pharma Vision AG, Montana Switzerland, Trygg-Hansa, Aga AB, and Tularik.


Top of Page
Print Version